GLP-1 Eligibility & Access FAQ: Do You Qualify for Semaglutide or Tirzepatide?

GLP-1 Eligibility & Access FAQ: Do You Qualify?

GLP-1 receptor agonists like semaglutide and tirzepatide have become the most effective medications for weight loss — but qualifying for treatment depends on specific medical criteria. Whether you're asking "do I qualify for GLP-1 weight loss medication," "what is the BMI requirement for Wegovy," or "can I get semaglutide online without a prior doctor visit," this guide answers the most common questions about eligibility, BMI requirements, and how to access GLP-1 medications through telehealth.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Eligibility for GLP-1 medications must be determined by a licensed healthcare provider based on your individual medical history. Telehealth Ally does not prescribe medications.

Do I qualify for GLP-1 weight loss medication?

The core eligibility criteria for FDA-approved GLP-1 weight loss medications (Wegovy, Zepbound) are based on BMI (Body Mass Index) and related health conditions:

You likely qualify if you have:

• BMI ≥ 30 (classified as obesity), OR
• BMI ≥ 27 with at least one weight-related comorbidity:
  • Type 2 diabetes
  • Hypertension (high blood pressure)
  • Dyslipidemia (high cholesterol/triglycerides)
  • Obstructive sleep apnea
  • Cardiovascular disease

Additional considerations:

• You should have tried diet and exercise without achieving adequate weight loss
• You must not have contraindications (see below)
• A licensed medical provider must evaluate your full medical history

BMI calculator context: BMI is calculated as weight (kg) / height (m²). A 5'7" person weighing 190 lbs has a BMI of ~29.8. At 195 lbs, they cross the 30 threshold. BMI is an imperfect measure — it doesn't account for muscle mass, bone density, or fat distribution — but it remains the standard clinical criterion for these medications.

What are the BMI requirements for Wegovy?

Wegovy (semaglutide 2.4mg) FDA-approved criteria:

These criteria come directly from the Wegovy prescribing information and the FDA approval based on the STEP clinical trial program.

What counts as a weight-related comorbidity:

• Type 2 diabetes or prediabetes (HbA1c ≥ 5.7%)
• Hypertension (≥ 130/80 mmHg or on medication)
• Dyslipidemia (elevated LDL, triglycerides, or on statin therapy)
• Obstructive sleep apnea (diagnosed or suspected)
• Nonalcoholic fatty liver disease (NAFLD)
• Cardiovascular disease

Note: Some insurers apply stricter criteria than the FDA label. They may require documented failure of lifestyle interventions, higher BMI thresholds, or step therapy (trying other medications first).

Can I get semaglutide online through telehealth?

Yes. Multiple telehealth platforms now offer GLP-1 prescriptions after a virtual medical evaluation. The process is typically:

1. Online intake: Complete a health questionnaire covering medical history, current medications, allergies, and weight loss goals
2. Virtual consultation: Video or asynchronous visit with a licensed physician, nurse practitioner, or physician assistant
3. Lab work: Some providers require labs before or shortly after starting treatment
4. Prescription: If medically appropriate, you receive a prescription for semaglutide
5. Medication delivery: Shipped to your home (compounded) or sent to your local pharmacy (brand-name)
6. Ongoing monitoring: Regular check-ins and dose adjustments per protocol

What to evaluate in a telehealth provider:

• Are they prescribing brand-name or compounded medication?
• Is the prescribing provider licensed in your state?
• Do they require lab work? (Providers that skip labs may be cutting corners)
• What is the follow-up/monitoring schedule?
• What happens if you experience side effects?
• What is the cancellation policy?

For detailed comparisons of telehealth GLP-1 providers, see our provider reviews and provider comparison page.

Do I need a referral or prior doctor visit to get GLP-1 medication?

No referral is needed for most telehealth programs or direct-to-consumer GLP-1 services. You can initiate treatment directly through a telehealth platform.

However, you still need:

• A medical evaluation by a licensed provider (conducted virtually)
• Appropriate documentation of your health history
• Lab work (varies by provider — some require it upfront, others order it as part of the program)

When you might need a referral:

• If your insurance requires a primary care referral for specialist visits
• If you're using an endocrinologist or obesity medicine specialist (some require referral)
• If your employer's health plan mandates referrals for prescription medications

Recommendation: Even if you use a telehealth provider for GLP-1 access, inform your primary care physician. They need to know about all medications you're taking, especially one that affects metabolic function, to coordinate your overall care.

What health conditions might disqualify me from GLP-1 treatment?

Absolute contraindications (do not use):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to semaglutide, tirzepatide, or any product components
• Pregnancy or planned pregnancy (discontinue at least 2 months before conception for semaglutide; 1 month for tirzepatide)
• Breastfeeding (insufficient safety data)

Relative contraindications (use with caution; provider discretion):

• History of pancreatitis — GLP-1 agonists have been associated with rare cases of acute pancreatitis
• Severe gastrointestinal disease (gastroparesis, inflammatory bowel disease) — GLP-1s slow gastric emptying
• Diabetic retinopathy — rapid glycemic improvement can temporarily worsen retinopathy
• Gallbladder disease — weight loss increases gallstone risk; GLP-1s may add to this
• Severe renal impairment — dose adjustments may be needed
• History of suicidal ideation or behavior — FDA requires monitoring (based on post-marketing reports, though clinical trial data did not show increased risk)

Important: These contraindications are why a proper medical evaluation is essential before starting GLP-1 therapy. Providers that prescribe without reviewing your medical history are not following standard of care.

Can I get GLP-1 medication if I don't have diabetes?

Yes. Two GLP-1 medications are specifically FDA-approved for weight loss in people without diabetes:

• Wegovy (semaglutide 2.4mg) — approved June 2021 for chronic weight management
• Zepbound (tirzepatide) — approved November 2023 for chronic weight management

You do not need a diabetes diagnosis. The approval is based on BMI criteria alone (or BMI with non-diabetes comorbidities like hypertension).

The clinical evidence:

• STEP 1 (Wegovy): 14.9% mean weight loss in non-diabetic adults over 68 weeks (Wilding et al., NEJM 2021)
• SURMOUNT-1 (Zepbound): Up to 22.5% mean weight loss in non-diabetic adults over 72 weeks (Jastreboff et al., NEJM 2022)

What about Ozempic and Mounjaro? These are FDA-approved for type 2 diabetes. Prescribing them for weight loss in non-diabetic patients is "off-label" — legal and common, but may face insurance coverage challenges. Your provider can explain the options.

What is the minimum BMI for weight loss medication?

The FDA-approved minimum BMI thresholds for GLP-1 weight loss medications:

Context: A BMI of 27 with comorbidities represents a patient who is overweight and already experiencing health consequences of excess weight. A BMI of 30 represents clinical obesity.

If your BMI is below 27: GLP-1 medications are generally not indicated. Cosmetic weight loss is not an approved use. Some telehealth providers may have lower thresholds, but this falls outside FDA-approved labeling and standard clinical guidelines.

Height/weight examples (BMI ~27 and ~30):

Can adolescents or teenagers use GLP-1 medications?

Wegovy is FDA-approved for adolescents aged 12 and older with obesity (BMI at or above the 95th percentile for age and sex).

Clinical evidence:

• STEP TEENS (Wegström et al., NEJM 2022): Adolescents on Wegovy achieved 16.1% reduction in BMI vs. 0.6% with placebo over 68 weeks
• The safety profile in adolescents was consistent with adult studies

Important considerations for parents:

• Treatment should be part of a comprehensive program including nutrition counseling and physical activity
• A pediatric endocrinologist or adolescent medicine specialist should manage treatment
• Long-term safety data in adolescents is still limited
• The decision should involve the adolescent, parents, and medical team

Other GLP-1 medications in adolescents:

• Mounjaro/Zepbound: not yet approved for patients under 18 (trials ongoing)
• Saxenda (liraglutide): approved for adolescents 12+ with obesity

How do I get started with a telehealth GLP-1 program?

Step-by-step process (typical):

1. Choose a provider — Compare telehealth platforms on our providers page. Consider: medication options (brand vs. compounded), pricing, included services, and monitoring approach.

2. Complete the intake — Fill out a detailed health questionnaire. Be thorough and honest — this information determines whether the medication is safe for you.

3. Virtual consultation — Meet with a licensed provider via video or asynchronous messaging. They'll review your history, discuss goals, and explain the medication.

4. Lab work — If required, complete blood work. Some providers send at-home lab kits; others accept recent results from your PCP (typically within 3–6 months).

5. Receive your prescription — If approved, medication ships to your home (compounded) or a prescription is sent to your local pharmacy (brand-name). Typical delivery: 3–7 days.

6. Start treatment — Begin at the lowest dose and follow the prescribed escalation schedule. Report any side effects promptly.

7. Follow-up visits — Attend scheduled check-ins (monthly is typical). Your provider will adjust dosing, monitor progress, and address any concerns.

Timeline: From signing up to receiving medication usually takes 5–14 days, depending on lab requirements and provider processing times.

Do telehealth providers prescribe brand-name or compounded GLP-1 medications?

This varies significantly by provider:

Brand-name only providers:

• Prescribe Wegovy, Ozempic, Mounjaro, or Zepbound
• Prescription sent to retail pharmacy (CVS, Walgreens, etc.) or shipped via manufacturer partnerships (e.g., LillyDirect for Zepbound vials)
• You handle insurance/payment at the pharmacy
• FDA-approved products with full clinical trial data
• LifeMD has direct partnerships with Novo Nordisk and Eli Lilly for negotiated brand-name pricing

Compounded-only providers:

• Prescribe compounded semaglutide or tirzepatide
• Medication shipped directly from a compounding pharmacy
• Price is typically bundled with the program fee
• Not FDA-approved products (see compounded vs. brand FAQ)
• Note: The compounded GLP-1 market is evolving — some providers (like Hims) are transitioning toward brand-name medications following manufacturer settlements

Providers offering both:

• Let you choose based on insurance coverage, cost preference, and risk tolerance
• Can help transition between options if availability changes
• Mochi Health and Lemonaid Health offer both compounded and brand-name options

New access points (2026):

• Oral Wegovy (semaglutide pill) — Now available through LifeMD and select providers for patients who prefer tablets over injections
• Walgreens — Now offering GLP-1 consultations at retail locations ($49/visit)
• Medicare coverage — $50/month copay cap starting April 2026 makes brand-name GLP-1s newly accessible to Medicare beneficiaries

Check our provider reviews for details on each platform's medication options.

Can I switch from one GLP-1 medication to another?

Yes, medication switches are common and medically appropriate in several scenarios:

Common switch patterns:

• Ozempic → Wegovy: Same molecule, but Wegovy allows a higher maintenance dose (2.4mg vs. 2.0mg). No washout period needed.
• Semaglutide → Tirzepatide: Different mechanism (GIP/GLP-1 dual agonist). Your provider will restart dose escalation from the beginning.
• Brand → Compounded: Dose equivalency and potency may differ. Provider guidance is essential.
• Compounded → Brand: May be necessary if compounded supply is disrupted. Dose adjustment required.

What to expect during a switch:

• Temporary increase in GI side effects as your body adjusts
• Provider-managed dose titration schedule
• Continued monitoring of weight, metabolic markers, and side effects

Do not switch medications on your own. Always consult your prescribing provider, who will determine appropriate dosing and monitor the transition.

What lab work is required before starting GLP-1 treatment?

Commonly required labs:

Additional labs some providers request:

• Vitamin B12 (GLP-1s may reduce absorption)
• Insulin level (assess insulin resistance)
• Vitamin D
• Pregnancy test (for women of childbearing age)

Frequency of ongoing monitoring: Most providers recheck labs at 3–6 month intervals during treatment.

If your provider doesn't require any labs: This should raise questions. While not every test is mandatory, some baseline assessment of kidney function, thyroid status, and metabolic markers is standard of care before prescribing GLP-1 medications.

Related Resources

• Medicare GLP-1 Coverage Guide — Part D now covers GLP-1s for weight loss
• GLP-1 April 2026 Price Changes — Everything shifting this month
• GLP-1 Cost & Insurance FAQ — Pricing, coverage, and savings programs
• GLP-1 Side Effects & Safety FAQ — What to expect and when to seek help
• Provider Reviews — Compare telehealth platforms
• Provider Comparison — Side-by-side provider features and pricing
• Semaglutide vs Tirzepatide — Choosing between the two leading options